Literature DB >> 8151765

Analysis of adeno-associated virus (AAV) wild-type and mutant Rep proteins for their abilities to negatively regulate AAV p5 and p19 mRNA levels.

S R Kyöstiö1, R A Owens, M D Weitzman, B A Antoni, N Chejanovsky, B J Carter.   

Abstract

The rep gene of adeno-associated virus type 2 (AAV) encodes four overlapping Rep proteins that are involved in gene regulation and replication of the virus. We studied here the regulation of mRNA transcribed from the AAV p5 and p19 promoters, using transient expression in human 293 cells followed by Northern (RNA) blot analysis of the mRNA. The p5 transcript encodes the larger Rep proteins, Rep78 and Rep68, while the p19 transcript encodes the smaller proteins, Rep52 and Rep40. A plasmid (pNTC3) containing the entire AAV genome with an amber mutation in the rep gene accumulated higher levels of p5 and p19 mRNA than a plasmid containing the wild-type AAV genome. Addition of increasing amounts of the wild-type rep gene in trans from a heterologous promoter inhibited p5 and p19 mRNA accumulation from pNTC3, indicating that the levels of both transcripts were decreased by the Rep proteins. Cotransfections with plasmids producing individual wild-type Rep proteins in trans showed that p5 and p19 mRNA accumulation was inhibited 5- to 10-fold by Rep78 and Rep68 and 2- to 3-fold by Rep52 and Rep40. Analysis of carboxyl-terminal truncation mutants of Rep78 showed that the ability of Rep78 to decrease p5 and p19 mRNA levels was lost when 159 or more amino acids were deleted. Rep78 and Rep68 mutants deleted for the methionine at residue 225 showed decreased abilities to down-regulate both p5 and p19 transcript levels, while mutants containing a substitution of glycine for the methionine resembled the wild-type Rep78. A Rep78 protein with a mutation in the putative nucleoside triphosphate binding site inhibited expression from p5 but not from p19, suggesting that the regulation of p5 transcript levels by Rep78 and Rep68 differs from that of p19. A deletion analysis of AAV cis sequences revealed that an intact terminal repeat was not required for negative regulation of p5 and p19 transcript levels and that the regulation of p19 mRNA levels by Rep78 did not require the presence of the p5 promoter.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151765      PMCID: PMC236783     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  46 in total

1.  Characteristics of a human cell line transformed by DNA from human adenovirus type 5.

Authors:  F L Graham; J Smiley; W C Russell; R Nairn
Journal:  J Gen Virol       Date:  1977-07       Impact factor: 3.891

2.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

3.  A technique for radiolabeling DNA restriction endonuclease fragments to high specific activity.

Authors:  A P Feinberg; B Vogelstein
Journal:  Anal Biochem       Date:  1983-07-01       Impact factor: 3.365

4.  Replication of adeno-associated virus in synchronized cells without the addition of a helper virus.

Authors:  B Yakobson; T Koch; E Winocour
Journal:  J Virol       Date:  1987-04       Impact factor: 5.103

5.  Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide.

Authors:  E Mendelson; J P Trempe; B J Carter
Journal:  J Virol       Date:  1986-12       Impact factor: 5.103

6.  Latent infection of KB cells with adeno-associated virus type 2.

Authors:  C A Laughlin; C B Cardellichio; H C Coon
Journal:  J Virol       Date:  1986-11       Impact factor: 5.103

7.  Positive and negative autoregulation of the adeno-associated virus type 2 genome.

Authors:  M A Labow; P L Hermonat; K I Berns
Journal:  J Virol       Date:  1986-10       Impact factor: 5.103

8.  Genetic analysis of adeno-associated virus: properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function.

Authors:  J D Tratschin; I L Miller; B J Carter
Journal:  J Virol       Date:  1984-09       Impact factor: 5.103

9.  Negative and positive regulation in trans of gene expression from adeno-associated virus vectors in mammalian cells by a viral rep gene product.

Authors:  J D Tratschin; J Tal; B J Carter
Journal:  Mol Cell Biol       Date:  1986-08       Impact factor: 4.272

10.  Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses.

Authors:  H E Gendelman; W Phelps; L Feigenbaum; J M Ostrove; A Adachi; P M Howley; G Khoury; H S Ginsberg; M A Martin
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

View more
  49 in total

1.  Factors affecting the terminal resolution site endonuclease, helicase, and ATPase activities of adeno-associated virus type 2 Rep proteins.

Authors:  J Wu; M D Davis; R A Owens
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins.

Authors:  J Hermanns; A Schulze; P Jansen-Db1urr; J A Kleinschmidt; R Schmidt; H zur Hausen
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

Review 3.  Cardiac gene therapy: from concept to reality.

Authors:  Razmig Garo Kratlian; Roger J Hajjar
Journal:  Curr Heart Fail Rep       Date:  2012-03

4.  Efficient replication of adeno-associated virus type 2 vectors: a cis-acting element outside of the terminal repeats and a minimal size.

Authors:  G E Tullis; T Shenk
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

5.  Control of adeno-associated virus type 2 cap gene expression: relative influence of helper virus, terminal repeats, and Rep proteins.

Authors:  S Weger; A Wistuba; D Grimm; J A Kleinschmidt
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  High mobility group chromosomal protein 1 binds to the adeno-associated virus replication protein (Rep) and promotes Rep-mediated site-specific cleavage of DNA, ATPase activity and transcriptional repression.

Authors:  E Costello; P Saudan; E Winocour; L Pizer; P Beard
Journal:  EMBO J       Date:  1997-10-01       Impact factor: 11.598

7.  Birth of a new therapeutic platform: 47 years of adeno-associated virus biology from virus discovery to licensed gene therapy.

Authors:  Terence R Flotte
Journal:  Mol Ther       Date:  2013-11       Impact factor: 11.454

8.  Human adeno-associated virus type 5 is only distantly related to other known primate helper-dependent parvoviruses.

Authors:  U Bantel-Schaal; H Delius; R Schmidt; H zur Hausen
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

9.  The cellular transcription factor SP1 and an unknown cellular protein are required to mediate Rep protein activation of the adeno-associated virus p19 promoter.

Authors:  D J Pereira; N Muzyczka
Journal:  J Virol       Date:  1997-03       Impact factor: 5.103

10.  Negative regulation of the adeno-associated virus (AAV) P5 promoter involves both the P5 rep binding site and the consensus ATP-binding motif of the AAV Rep68 protein.

Authors:  S R Kyöstiö; R S Wonderling; R A Owens
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.